Brief: Maat Pharma Announces EMA Orphan Drug Designation For Maat033
07/09/2023 06:35
Sept 7 (Reuters) - Maat Pharma SA MAAT.PA :
* MAAT PHARMA ANNOUNCES EUROPEAN MEDICINES AGENCY GRANTED
MAAT033
ORPHAN DRUG DESIGNATION AIMING TO IMPROVE OVERALL SURVIVAL IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Source text for Eikon: ID:nBw5SGH6ja
Further company coverage: MAAT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026